Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Asset Writedowns and Impairment: 2017-2022

  • UNITED THERAPEUTICS's Asset Writedowns and Impairment was N/A to $4.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $130.0 million, marking a year-over-year change of. This contributed to the annual value of $3.6 million for FY2023, which is 67.86% down from last year.
  • UNITED THERAPEUTICS's Asset Writedowns and Impairment amounted to $4.2 million in Q4 2022, which was down 40.00% from $7.0 million recorded in Q3 2022.
  • In the past 5 years, UNITED THERAPEUTICS's Asset Writedowns and Impairment registered a high of $113.4 million during Q1 2021, and its lowest value of -$400,000 during Q3 2019.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $6.2 million (2020), whereas its average is $32.5 million.
  • Data for UNITED THERAPEUTICS's Asset Writedowns and Impairment shows a peak YoY skyrocketed of 1,450.00% (in 2020) over the last 5 years.
  • UNITED THERAPEUTICS's Asset Writedowns and Impairment (Quarterly) stood at $8.8 million in 2019, then spiked by 1,450.00% to $5.4 million in 2020, then reached $113.4 million in 2021, then reached $4.2 million in 2022.
  • Its last three reported values are $4.2 million in Q4 2022, $7.0 million for Q3 2022, and $113.4 million during Q1 2021.